Friday, May 9, 2025 5/9/2025

Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models

Award Number: U01CA250549
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models - Abstract Experimental models of cancer provide the means both to decipher the molecular basis of cancer and to develop new therapeutic agents. To date, most cancer research has employed established cancer cell lines and genetically engineered mouse models. Although these models have provided tremendous insight into many aspects of cancer initiation and progression, each of these models has important limitations, including adaptation to culture (cell lines), lack of genomic instability (mouse models), and inadequate representation of the spectrum of mutations and subtypes of human cancers. Next generation cancer models (NGCMs) such as organoid models have recently been developed. NGCMs address many deficits of prior models and promise to accelerate cancer research and experimental therapeutic efforts. Recent methodological advances now make it possible to create patient-derived cancer cell lines and organoids with increased efficiency. When coupled with genomic analysis, these new models may facilitate new insights into human cancers. However, organoids require complex culture conditions and display distinct properties that pose challenges for implementation of standard molecular and cell biology techniques. To facilitate widespread use of organoid models within the research community, we must develop innovative technologies to overcome these challenges and enable study of organoids for a range of cancer phenotypes. In this Project, we will build on our expertise in the development of genome scale and informatic methods as well as our work to derive many of the HCMI models with the goal of developing high throughput approaches to perform genetic and small molecule screens in patient-derived organoids created by the Human Cancer Models Initiative (HCMI). In addition, we will use innovative methods to interrogate cell state plasticity and heterogeneity in these models. These studies will allow the cancer research community to perform both high and low throughput analyses in patient-derived models and to provide deep insight into the stability and phenotypes represented by these models. While we will focus our technology development efforts using pancreatic cancer organoids, we anticipate that the approaches developed in this proposal will be widely applicable to many different models from a range of cancer types. In Aim 1, we will develop and implement a highly multiplexed method to screen patient-derived organoid models with both small molecules and genetic reagents. These studies will provide a powerful approach to interrogating HCMI models at high throughput. In Aim 2, we will build on our preliminary studies that indicate that patient-derived organoids exhibit heterogeneity and rapid shifts in expressed phenotypes. We will interrogate the dynamics of these state changes and assess the degrees of heterogeneity in these models using newly developed physical and sequencing methodology. In Aim 3, we will build on Project Achilles and the DepMap (www.DepMap.org) to create and implement an optimized genome scale CRISPR-Cas9 library that permits the systematic genetic interrogation of genetic dependencies in patient-derived organoids. We anticipate that these studies will create new methods that permit rigorous evaluation of HCMI models as well as the discovery of novel biomarkers and therapeutic targets in pancreatic cancer. More broadly, these studies will provide critical proof of principle that these methods can be used by others to study specific phenotypes in next generation cancer models such as organoids.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$14,946 )
2024	2022	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	3	3/21/2024	NON-COMPETING CONTINUATION	-$14,946
														Subtotal = -$14,946

Issue Date FY: 2022 ( Subtotal = $963,693 )
2022	2022	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	001	3	5/16/2022	NON-COMPETING CONTINUATION	$963,693
2022	2021	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	2	2/7/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $963,693

Issue Date FY: 2021 ( Subtotal = $963,150 )
2021	2021	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	2	7/29/2021	NON-COMPETING CONTINUATION	$963,150
														Subtotal = $963,150

Issue Date FY: 2020 ( Subtotal = $1,004,910 )
2020	2020	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	6/8/2020	NEW	$1,004,910
														Subtotal = $1,004,910

Grand Total All Awards = $2,916,807

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models

Award Number: U01CA250549

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer